GAINESVILLE, Florida – (COMMERCIAL THREAD) –Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical-stage biotechnology company dedicated to the development of life-changing drugs through science and innovation for patients and families living with diseases, today announced the appointment of Cynthia A. Lemere, PhD as Senior Advisor for its Alzheimer’s Disease Program.
Dr Lemere is a distinguished scientist currently working at the Ann Romney Center for Neurologic Diseases at Brigham and Women’s Hospital (BWH) and as an Associate Professor of Neurology at Harvard Medical School in Boston. She was a pioneer in the use of antibodies against beta-amyloid for the prevention or treatment of Alzheimer’s disease. Beginning in 1997, his research lab focused on the role of inflammation and the immune system in the onset of Alzheimer’s disease, paving the way for the identification of drug development targets to prevent or treat Alzheimer’s disease. His lab is funded by the National Institutes of Health (NIH), NASA, and private foundations. Dr. Lemere has served as a mentor to numerous doctoral and postdoctoral students, helping to develop the next generation of leaders in the field of Alzheimer’s disease, and she is a much sought-after advisor to the public sector and private groups.
“There remain significant unmet medical needs in the treatment of this devastating disease. As we continue to advance the evaluation of Trappsol® Cyclo ™ for the treatment of Alzheimer’s disease, we are pleased to welcome Dr Lemere to the team. His groundbreaking research and contributions to the understanding and therapeutic use of the immune system to prevent and treat Alzheimer’s disease is a valuable asset that we believe will provide an insightful perspective as we work to enter a study of phase 2 on this disease and advance this critical program, ”commented Lise Lund Kjems, MD, PhD, Chief Medical Officer of Cyclo Therapeutics.
“Dr. Lemere is a highly recognized and established thought leader in Alzheimer’s disease research. His leadership, expertise and passion are notable additions to Cyclo Therapeutics, and they are in line with our own dedication to helping patients and families suffering from this insidious disease.We continue to be encouraged by the potential of Trappsol® Cyclo ™ and we look forward to further development for Alzheimer’s disease, ”added Sharon Hrynkow, PhD, Scientific Director and Senior Vice President of Medical Affairs, Cyclo Therapeutics.
Dr. Lemere’s current research includes non-clinical studies of antibody treatments targeting a pathogenic form of the beta-amyloid protein in Alzheimer’s disease; the role of complement signaling in aging and Alzheimer’s disease; and the effects of galactic cosmic radiation in deep space on brain aging and the risk of Alzheimer’s disease in studies of mouse models and human neural cells in preparation for NASA’s first manned mission to Mars in the United States. 2030s. She is a member and past president of the medical and scientific advisory group of the Alzheimer’s Association and former member of the Association’s board of directors. She is also a member of Cure Alzheimer’s Fund Research Leadership Group. In addition, she is a scientific advisor for several foundations, conferences and companies.
“Physicians and families within the Alzheimer’s disease community continue to face significant unmet medical needs. I believe the positive results that have been demonstrated by Trappsol Cyclo / beta cyclodextrins to date in preclinical studies and the Company’s compassionate use program are encouraging and reaffirm its continued development. I am delighted to join this dedicated team to help advance the development of Trappsol Cyclo for the treatment of Alzheimer’s disease as quickly and effectively as possible, ”added Dr. Lemere.
Dr Lemere received a BA in Psychology and Education from Mount Holyoke College and an MA in Neurobiology from SUNY Albany. She then looked at brain changes linked to Alzheimer’s disease in people with Down syndrome at BWH’s Selkoe Lab while pursuing her doctorate in pathology at Boston University School of Medicine. After obtaining her doctorate, she remained at the BWH Ann Romney Center for Neurologic Diseases in the Department of Neurology where she is an associate professor.
Cyclo Therapeutics plans to evaluate Trappsol® Cyclo ™, the company’s proprietary formulation of hydroxypropyl beta cyclodextrin, for the treatment of Alzheimer’s disease, targeting the reduction of beta-amyloids and tau. In a Type B Interaction with the FDA, Cyclo Therapeutics Received Positive Feedback Supporting the Company’s Development Strategy to Submit an IND Application for a Phase 2 Intravenous Trappsol Study® Cyclo ™ in the treatment of early-onset Alzheimer’s disease. The Company is in the process of filing its IND for a Phase 2 study in Alzheimer’s disease before the end of 2021.
About Cyclo Therapeutics
Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to the development of life-changing drugs through science and innovation for patients and families with disease. The company’s Trappsol® Cyclo ™, a drug designated orphan drug in the United States and Europe, is the subject of four formal clinical trials for Niemann-Pick disease type C, a rare and fatal genetic disorder (www.ClinicalTrials.gov NCT02939547, NCT02912793, NCT03893071 and NCT04860960). Company plans early phase clinical trial using Trappsol® Intravenous Cyclo ™ in Alzheimer’s disease based on encouraging data from an expanded access program for late-onset Alzheimer’s disease (NCT03624842). Additional indications for the active substance in Trappsol® Cyclo ™ are in development. For more information, visit the Company’s website: www.cyclotherapeutics.com.
Safe Harbor Declaration
This press release contains “forward-looking statements” regarding the Company’s current expectations regarding future results, performance, prospects and opportunities, including, without limitation, statements regarding the satisfaction of the relative closing conditions. to the offer and the intended use of the proceeds of the offer. Statements that are not historical facts, such as “anticipate”, “believe” and “expect” or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed or implied in such statements. Factors likely to influence the future performance of the company include the ability of the company to raise additional capital to develop its business as planned, the success of obtaining regulatory approval for clinical protocols, the recruitment of sufficient numbers of patients in clinical trials, unforeseen difficulties in demonstrating efficacy of biopharmaceuticals, success in attracting additional customers and profitable contracts, and regulatory risks associated with the production of pharmaceutical and food grade products. These and other risk factors are described from time to time in the company’s filings with the Securities and Exchange Commission, including, but not limited to, the company’s reports on Form 10-K and 10-Q. Except as required by law, the company assumes no obligation to update or revise forward-looking statements as a result of new information or future events.